Pharmaceutical Reimbursement in Poland: A 2025 Deep Dive

Poland’s pharmaceutical reimbursement system remains one of Europe’s most structured, evidence-driven, and economically disciplined models. For manufacturers, health-economics teams, and policy specialists, understanding how drug reimbursement operates in Poland is essential for navigating pricing, access, and HTA strategy. In 2025, AOTMiT’s rigorous HTA assessments, NFZ’s cost-control mechanisms, and the Ministry of Health’s strong national pricing authority shape every reimbursement outcome. The result is a uniquely transparent yet highly competitive environment where clinical evidence, cost-effectiveness, and budget impact determine whether a medicine receives public funding.

Understanding the structure of pharmaceutical reimbursement in Poland is not only important from a policy perspective—it provides a practical roadmap for how companies can successfully plan market entry, pricing, and HTA strategy. When used effectively, the Polish reimbursement process becomes a step-by-step framework: manufacturers can analyse AOTMiT’s previous HTA assessments to identify evidence gaps, design economic models that align with NFZ budget expectations, and anticipate negotiation scenarios with the Ministry of Health. HEOR teams can leverage the system’s transparency to benchmark ICER thresholds, compare reimbursement outcomes across therapeutic classes, and optimise real-world evidence generation. Even early-stage biotech and innovators can use Poland’s structured process to forecast timelines, validate pricing assumptions, and prepare stronger reimbursement dossiers for multiple European markets.

Why Pharmaceutical Reimbursement Matters in Poland

Unlike MedTech or digital health where reimbursement is fragmented, regionally variable, and often dependent on hospital contracting, pharmaceutical reimbursement in Poland is centrally legislated, tightly codified, and nationally enforced. This means that every drug entering the Polish healthcare system must pass through a clearly defined pathway that integrates clinical evidence, health technology assessment, pricing negotiations, and payer budget constraints.

Three features make Poland’s approach especially distinctive:

AOTMiT as a powerful national HTA authority, applying rigorous assessments of clinical effectiveness, cost-effectiveness, and budget impact.
Strong ministerial control over pharmaceutical pricing, reimbursement status, indications, and commercial conditions.
NFZ’s cost-conscious funding model, driven by co-payments, reference pricing, and strict budget impact thresholds.

Together, these mechanisms create a predictable, disciplined, and economically oriented reimbursement environment—one where evidence must be robust, economic models must be defensible, and price negotiations must be strategically aligned with payer priorities.

A Highly Disciplined HTA Framework

AOTMiT: The Centre of Evidence-Based Decision-Making

Although Poland no longer publishes an official cost-effectiveness threshold, AOTMiT continues to apply the long-standing benchmark of up to 3×GDP per capita per QALY gained, corresponding to roughly PLN 230,000–250,000 (≈ €50,000–55,000) per QALY in 2024. This implicit threshold guides HTA recommendations, especially for low-budget-impact medicines. However, high-impact areas such as oncology face tighter practical limits, where acceptable ICERs may fall to 1–2×GDP per QALY due to NFZ affordability constraints. Manufacturers must submit robust QALY modelling, apply Polish EQ-5D value sets, and address long-term uncertainty to meet AOTMiT requirements.

Over these 20 years, AOTMiT’s goal has been to support decision-making in the healthcare system by providing comprehensive health technology assessment (HTA) information. Until April 2025, the AOTMiT has issued 2,790 opinions on HPPs and made 27 recommendations. The majority of the HPPs focused on vaccinations (>1,000), oncology (nearly 400), rehabilitation (>300), dentistry (>150), and in vitro fertilisation (>100). For most of these health issues, recommendations were issued later, standardising the actions taken by LGUs. LGUs are also required to submit a final report to AOTMiT, detailing outcomes and evaluating the effectiveness of actions. From 2018 to 2025, 971 final reports were submitted.

Poland’s Agency for Health Technology Assessment and Tariff System (AOTMiT) functions as the scientific engine behind the entire pharmaceutical reimbursement system. No medicine can enter public funding without passing through a full HTA evaluation, making AOTMiT one of the most influential national HTA bodies in Europe. Its assessments incorporate a comprehensive set of criteria, including:

Clinical effectiveness
Comparative effectiveness vs. standard of care
Cost-effectiveness modelling (commonly using QALYs and ICERs)
Budget impact analysis (BIA)
Organisational, ethical, and societal considerations

pharmaceutical reimbursement in Poland. Few countries apply this breadth of assessment to every reimbursed medicine, which is why Poland consistently ranks alongside England, Sweden, and Germany in comparative HTA studies. AOTMiT plays a central role in pharmaceutical reimbursement in Poland and is increasingly important across Europe.

Among Central and Eastern European markets, it is seen as one of the most methodologically mature HTA bodies, closely aligned with NICE, TLV and IQWiG. Because of this, a positive AOTMiT recommendation often supports later submissions in countries such as Czechia, Slovakia, Hungary and the Baltic states. Payers and policymakers in these systems treat Polish HTA as a practical benchmark, which quietly increases Poland’s strategic weight in regional pricing and reimbursement decisions.

Although Poland no longer uses a formal willingness-to-pay threshold, the former 3×GDP per capita rule still shapes pharmaceutical reimbursement in Poland. It acts as a cultural reference point for HTA reviewers, economic modellers, and payers. In practice, oncology and high-budget therapies face tighter expectations—often closer to 1–2×GDP per QALY—because NFZ affordability now drives final decisions. This implicit threshold helps manufacturers understand how AOTMiT interprets cost-effectiveness in real reimbursement scenarios.

Single Technology Assessments Dominate Polish HTA Practice

AOTMiT relies heavily on Single Technology Assessments (STAs), focusing on a specific medicine relative to its closest comparators. Methodologically, Poland aligns strongly with ISPOR, EUnetHTA, and NICE standards, requiring:

Systematic literature reviews
Survival extrapolations for oncology drugs
Health-state modelling (Markov or partitioned survival models)
Sensitivity analyses and probabilistic modelling

This scientific rigor ensures that manufacturers cannot rely on partial or selective evidence; they must provide comprehensive datasets, validated modelling assumptions, and transparent uncertainty analysis.

The Role of Cost-Effectiveness Thresholds

Although Poland does not publish a fixed ICER threshold, the system implicitly benchmarks cost-effectiveness against:

3 × GDP per capita per QALY (historically referenced in guidance)
Comparative ICERs of existing reimbursed therapies
Budget impact constraints set by NFZ

This effectively creates a de facto cost-effectiveness ceiling, forcing manufacturers to model realistic treatment effects, credible utility values, and baseline risk assumptions. Inflated clinical claims or misaligned comparators often lead to negative HTA outcomes.

Budget Impact as a Decisive Criterion

In Poland, budget impact is as important as incremental benefit. A drug may be clinically strong but still fail reimbursement if NFZ cannot sustain its population-level cost. AOTMiT requires:

Realistic uptake forecasts
Estimates of displaced therapies
Scenario analyses for different prescribing patterns
Consideration of indirect cost savings (e.g., reduced hospitalisation)

This emphasis on financial sustainability reflects Poland’s cost-sensitive payer model, where reimbursement must balance clinical need with affordability across both inpatient and outpatient settings.

Why This Matters for Manufacturers

The disciplined nature of Poland’s HTA system means that weak economic models, methodological shortcuts, or uncertain evidence rarely survive the process. Successful submissions require:

High-quality clinical evidence
A defensible economic model
Transparent methodological choices
Alignment with NFZ’s long-term budget strategy
Pricing that reflects both value and affordability

For pharmaceutical companies, mastering Poland’s HTA expectations is not optional—it is the determining factor between reimbursement success and rejection.

Early Access Pathways and Companion Diagnostics in Poland

While Poland’s formal reimbursement framework is highly structured, access to innovative medicines often begins well before a product receives a full reimbursement decision. Poland operates a set of mechanisms that together function as a national early-access ecosystem, particularly for oncology biologics, immunology treatments, rare disease therapies, and emerging ATMPs. These pathways bridge the gap between clinical need and reimbursement timelines, giving clinicians controlled access to breakthrough technologies while national HTA and pricing negotiations are still underway.

Early Access Through RDTL: Poland’s Emergency Pathway for Life-Threatening Conditions

Poland’s closest analogue to European early access schemes is Ratunkowy Dostęp do Technologii Lekowych (RDTL) — the Emergency Access to Drug Technologies pathway.
RDTL allows physicians to request a non-reimbursed or non-indicated medicine for a single patient with a life-threatening condition when no alternative therapy exists.

Key characteristics of RDTL include:

Requests are initiated by the treating physician.
The application is reviewed internally by the hospital director.
Final approval comes from the Minister of Health, not the NFZ.
AOTMiT is not involved at this stage, as RDTL precedes formal HTA.
Funding is drawn from a separate Ministry of Health budget, avoiding the delays of NFZ contracting.

RDTL is frequently used in oncology, haematology, metabolic rare diseases, and rapidly progressing conditions. It offers Poland’s fastest legal route for accessing innovation, often functioning as a “clinical gateway” to later full reimbursement. Many therapies that ultimately enter drug programmes begin their lifecycle in RDTL, building early clinical experience and generating real-world evidence.

Drug Programmes (B-Programmes): Controlled Early Access for Biologics and High-Cost Therapies

Poland’s B-programmes serve a dual purpose: they are both a reimbursement mechanism and an early-access structure for complex biologics and precision medicine.
These programmes define:

Eligibility criteria (e.g., biomarker status, prior lines of therapy)
Treatment algorithms and stopping rules
Required companion diagnostics
Follow-up schedules
Mandatory real-world data submission from hospitals

Unlike RDTL, B-programmes undergo full HTA by AOTMiT, including clinical review, cost-effectiveness modelling, and budget impact analysis. Once approved, NFZ funds the therapy nationally, allowing widespread clinical adoption before the product moves to broader outpatient reimbursement categories.

Because of their structure, B-programmes create a high degree of clinical governance, ensuring that innovative biologics are used precisely in the patient groups for whom they deliver the highest value. This model is increasingly important for oncology pipelines, immunotherapies, and rare disease biologics.

Poland’s drug programmes are central to how high-cost biologics enter pharmaceutical reimbursement. They allow earlier access while enforcing strict clinical criteria, monitoring rules and real-world evidence collection. This structure helps NFZ manage financial risk and helps AOTMiT reduce uncertainty around complex biologics. For manufacturers, B-Programmes offer a clear route into national funding, but only when clinical pathways and economic models are tightly aligned with Polish standards.

Ministerial Off-Label Reimbursement: Bridging Evidence Gaps

Another early-access mechanism is Poland’s ability to reimburse medicines outside their registered indication when strong medical rationale exists and unmet need is high.
Under Article 39 of the Reimbursement Act, the Minister of Health may authorise off-label use after consulting the Transparency Council and national clinical experts.

This pathway provides rapid access to medicines awaiting:

Updated EMA indications
Additional phase III evidence
Formal extension of drug programmes

It is particularly relevant for oncology and paediatric rare diseases, where therapeutic innovation often outpaces regulatory cycles.

Companion Diagnostics (CDx) and Precision Medicine Access in Poland

Companion diagnostics play a critical role in enabling targeted therapies, yet Poland does not operate a standalone reimbursement pathway for CDx. Instead, the method of funding depends on the therapeutic context and the care setting.

CDx Funded Inside Drug Programmes (The Most Common Pathway)

For oncology biologics and immunotherapies, CDx is typically funded within the drug programme itself. The NFZ allocates a combined budget covering:

Diagnostic testing (e.g., EGFR, ALK, BRAF, BRCA, PD-L1)
Drug acquisition costs
Monitoring and follow-up

When AOTMiT evaluates a new therapy requiring a biomarker, the cost and accuracy of the diagnostic test are integrated into the HTA submission.
This ensures that CDx is treated as a necessary enabler of the therapy rather than an optional add-on.

This model has been essential for expanding precision oncology in Poland and ensures equitable access to biomarker testing nationwide.

CDx in Inpatient DRG Tariffs

Certain molecular or immunohistochemical tests are funded as part of inpatient tariffs (JGP). However, DRG levels in Poland are often below the real cost of advanced molecular diagnostics, making NGS panels, multiplex biomarker assays, and HRD testing difficult to implement outside a structured drug programme.

Hospitals may adopt these tests, but only when the expected clinical value offsets the financial pressure created by tariff underfunding.

CDx in Outpatient Benefits

A smaller subset of diagnostics is included in the list of outpatient guaranteed benefits. These typically relate to:

Screening programmes
Genetic diagnostics for congenital disorders
Selected high-priority biomarkers

However, advanced CDx used in precision oncology or rare disease biologics rarely fall into this category.

The Emerging Role of Digital Diagnostics and Data-Driven Medicine

Although Poland lacks a national reimbursement pathway for digital health, advanced diagnostics and digital biomarkers increasingly support pharmaceutical and biotech value propositions.

Digital technologies strengthen reimbursement submissions by:

Improving real-world evidence (RWE) generation
Enhancing adherence tracking, symptom reporting, and treatment outcomes
Enabling outcome-based MEAs through continuous monitoring
Refining QALY modelling with higher-resolution patient-reported outcomes
Supporting companion diagnostics via algorithmic triage, radiogenomics, or AI-based pathology analysis

These tools do not yet receive reimbursement independently, but they are increasingly recognised by AOTMiT as components that reduce uncertainty in effectiveness, improve targeting, and therefore enhance cost-effectiveness.

As Poland moves toward EU HTA integration in 2025 and expands precision medicine adoption, digital diagnostics will play a larger supporting role in securing reimbursement for high-complexity biologics.

The Legal Backbone: The Reimbursement Act of 2011

Most European HTA systems evolved gradually. Poland, on the other hand, created a single, comprehensive legal framework—the Reimbursement Act of 12 May 2011 which still governs pricing, access, co-payments, and negotiations.

This Act defines:

How manufacturers file for reimbursement
HTA requirements
Transparency rules
Negotiation processes
Monitoring obligations
Co-payment structures
Reference pricing clusters

This legal certainty is a key advantage for companies: the rules do not change unpredictably, and the process is clearly mapped.

Although Poland’s Reimbursement Act dates back to 2011, it has undergone continuous amendments, with significant updates introduced between 2015 and 2024. The Ministry of Health initiated a major reform package in 2023, aiming to modernise pricing rules, MEAs, generic entry requirements, and drug supply obligations. However, political changes slowed implementation, leaving Poland in a transitional reimbursement environment. This means that while the Act remains the core legal backbone of pharmaceutical reimbursement, its operational rules are modern, frequently updated, and still evolving.

Reimbursement Reforms in 2023–2025

In 2023, Poland proposed a sweeping amendment of the Reimbursement Act—known as the “large amendment package” designed to redefine pricing, reimbursement timelines, pharmacy margins, wholesale rules, and obligations for consistent drug supply. The proposal also introduced stronger pricing cuts after loss of exclusivity and stricter MEA conditions. Although the package was not fully implemented following the 2023 elections, many of its concepts continue to influence policy direction in 2024–2025. Poland is therefore operating in a reform-sensitive environment where reimbursement rules are stable but expected to modernise further.

Impact of the EU HTA Regulation (2025)

From 2025 onward, the EU HTA Regulation fundamentally changes how clinical evidence is assessed for selected high-impact technologies, particularly oncology medicines and advanced therapies. AOTMiT will no longer conduct full clinical assessments for these categories but will rely on the joint EU clinical assessment (JCA). Poland will continue to perform economic evaluations and budget impact analyses, but the new EU framework will increase alignment, accelerate timelines, and shift part of the evidence burden to a centralised European process. Manufacturers preparing Polish submissions must now consider EU-level dossier requirements and synchronised evaluation timelines.

Recent Pricing and Access Changes (2022–2024)

Poland has introduced several policy changes affecting pricing pressure and access. Free medicines programmes for seniors, children, and pregnant women have significantly expanded since 2022, affecting reimbursement categories and payer behaviour. New mandatory price reductions tied to generic entry have strengthened Poland’s cost-containment strategy. Meanwhile, updated drug shortage regulations require manufacturers to maintain consistent supply to retain reimbursement status. Together, these measures reinforce Poland’s position as one of Europe’s most cost-focused pharmaceutical markets.

Evolution of Poland’s Oncology Drug Programmes

Oncology represents the largest share of NFZ drug expenditure, and Poland’s drug programmes (B programmes) have undergone important updates between 2022 and 2024. These include faster inclusion of new therapies, alignment with European clinical guidelines, and more structured cost-effectiveness evaluations. The reforms have increased transparency but also heightened scrutiny for high-cost medicines entering hospital and outpatient oncology pathways.

Pricing and Negotiation: A Highly Controlled Process

After HTA, price negotiation begins and this is where Poland diverges from most European systems.

The Economic Commission Negotiates Every Drug Price

This Commission discusses:

Official selling price
Indications for reimbursement
Co-payment category
Managed Entry Agreements (MEAs)
Budget caps and pay-back mechanisms

Types of MEA commonly used in Poland include:

Price discounts
Pay-by-performance agreements
Price-volume agreements
Budget caps with mandatory refunds

Poland’s MEA landscape is more conservative than Italy or the UK, but more structured than many Central/Eastern European countries.

Ministerial Approval is Final

Even with a positive HTA, a drug can be rejected if negotiations fail.
This gives the Polish system significant bargaining power—reflected in consistently low drug prices compared to EU averages.

Co-Payments and Reference Pricing: The Patient Perspective

Pharmaceutical co-payments in Poland remain relatively high, especially for multi-morbidity patients. Most reimbursed medicines require a 30–50% patient co-payment, unless:

They fall under a special “lump sum” category, or
They belong to protected therapeutic areas with capped costs.

Reference Pricing

This is Poland’s core cost-control mechanism. Drugs are grouped into clusters (ATC 3/4/5), and the public payer reimburses up to the reference price of the lowest-cost alternative.

This means:

Originators often have higher co-payments than generics
Patients are financially incentivised to choose cheaper alternatives
Manufacturers must carefully position their pricing strategy

The Untapped Power of Generic Substitution

The 2021 big-data study revealed a surprising insight: although Poland has strong incentives for generic use, substitution at the pharmacy level is far lower than expected.

Only 4.08% of metformin e-prescriptions were substituted for cheaper generics.

If this were optimised across all therapeutic areas:

Patients could save 15.9% on co-payments
The National Health Fund (NFZ) could reduce its spending by 8.3%

This exposes a critical opportunity: system design is strong, but implementation is inconsistent.

For policymakers, this represents low-hanging fruit.
For pharma companies, it highlights where price sensitivity is highest.

Stability and Predictability: The 2025 Perspective

The 2025 healthcare financing survey confirms that the core reimbursement architecture remains unchanged.

Key observations for 2025:

The Ministry of Health retains strict authority over pricing and reimbursement decisions.
AOTMiT continues to expand its technical capacity and influence.
Reimbursement lists are updated quarterly—far more frequently than many EU markets.
Co-payment pressures and inflation are driving renewed focus on tariff adjustments and cost-effectiveness.
No disruptive reforms have altered the pharmaceutical pathway.

In other words: what worked in 2021–2023 still works today—only with more financial pressure and more demand for economic evidence.

Why Pharmaceutical Reimbursement Dominates Over MedTech and Digital Health in Poland

From a strategic and health-economic perspective, Poland presents three fundamentally different reimbursement environments for pharmaceuticals, MedTech devices, and digital health technologies. These differences explain why pharmaceutical reimbursement remains the most structured, predictable, and strategically meaningful route to market access.

Pharmaceuticals: A Structured, Evidence-Driven, Predictable Pathway

Pharma benefits from Poland’s fully developed HTA and reimbursement architecture, where every medicine is assessed through AOTMiT’s rigorous framework:

Formal HTA with clinical and economic evaluation
Predictable submission cycles
National pricing negotiations
Legally defined reimbursement categories
Quarterly updates (Obwieszczenia Refundacyjne)
Strong payer oversight from NFZ and the Ministry of Health

The system ensures transparency and consistency. Manufacturers know:

What evidence is required
How the HTA will be interpreted
How pricing will influence co-payments and reference pricing
Which MEAs or budget caps are likely to apply

This level of structure does not exist in other Polish healthcare sectors, making pharmaceutical reimbursement the most dependable and strategically optimisable pathway.

MedTech: Fragmented Pathways and Economic Constraints

Unlike pharmaceuticals, MedTech reimbursement in Poland is not centralised. Devices fall into several disconnected funding mechanisms:

A. Hospital funding through DRG tariffs (JGP)

Most high-cost devices must be absorbed into underfunded inpatient tariffs, which have limited capacity to accommodate new technologies.
Hospitals often cannot adopt innovative devices without additional external funding.

B. Outpatient procedure tariffs

Some diagnostics or devices may be funded via guaranteed benefit baskets, but tariff levels are frequently misaligned with real costs, reducing adoption.

C. Limited HTA coverage

AOTMiT does not consistently evaluate all devices. HTA is typically reserved for:

High-impact technologies
Screening programmes
Selected diagnostic procedures

This creates uncertainty and inconsistent decision-making.

Economic impact:

MedTech companies face pricing compression, unpredictable pathways, and reliance on individual hospital budgets—none of which apply to pharmaceuticals.

Digital Health: Immature Pathways but Growing Strategic Value

Digital health does not yet have a national reimbursement pathway comparable to Germany’s DiGA system or Belgium’s M1–M3 process.

Current characteristics:

A. Telemedicine is funded, but…

Only the clinical service is reimbursed, not the underlying software.

B. Software-as-a-Medical-Device (SaMD)

Under IVDR, SaMD requires CE marking, but no dedicated reimbursement mechanism exists for digital therapeutics or advanced AI tools.

C. Local NFZ contracting

Some digital tools may be used under regional pilots, but there is no national funding line.

D. No HTA pathway

AOTMiT does not have a structured method for evaluating digital interventions.

In short:
Digital health can support clinical value but cannot independently achieve national reimbursement.

The Overlooked Element: Digital Health Strengthens Pharmaceutical Value

While digital tools lack standalone reimbursement, they can dramatically enhance pharmaceutical reimbursement submissions.

Digital technologies can:

A. Enable Companion Diagnostics (CDx)

CDx tools help:

Identify responders
Reduce treatment waste
Improve ICER outcomes
Strengthen HTA submissions for precision medicine

AOTMiT views companion diagnostics favourably when they reduce uncertainty around treatment effectiveness.

B. Collect Real-World Evidence (RWE)

Digital platforms produce high-quality data:

Adherence metrics
Symptom tracking
Longitudinal treatment outcomes
Polypharmacy management insights

RWE can support price renegotiation, MEA extensions, or new indication submissions.

C. Improve PRO (Patient Reported Outcome) Data Quality

Digital diaries and monitoring tools strengthen:

QALY calculations
Utility weight estimations
Treatment effect modelling

This has direct implications for cost-effectiveness modelling.

D. Support Risk-Sharing Agreements

Digital monitoring allows:

Real-world performance tracking
Outcome-based MEAs
Adaptive pricing

NFZ increasingly welcomes tools that allow tighter cost control.

Technology Type	Pathway	Predictability	Economic Rigor	Strategic Leverage
Pharmaceuticals	Formal HTA → Pricing Negotiation → Reimbursement List	⭐⭐⭐⭐⭐	⭐⭐⭐⭐⭐	Very High
MedTech	DRGs, tariffs, limited HTA	⭐⭐	⭐⭐	Moderate to Low
Digital Health	No national pathway	⭐	⭐	High only when paired with pharma

Poland’s pharmaceutical reimbursement system remains the most structured and stable pathway, delivering predictable rules, high transparency, and strong scientific requirements.

MedTech and digital health face fragmented, evolving, or immature pathways, but they can play a crucial supporting role—particularly in the rise of companion diagnostics, data-driven drug development, and digital evidence generation.

For manufacturers, integrating digital monitoring, PRO collection, and precision diagnostics into pharmaceutical submissions can materially improve:

HTA outcomes
ICERs
Negotiation leverage
Reimbursement success

This is where the future of Polish reimbursement strategy lies: pharmaceuticals enhanced by digital intelligence.

The Position of Biotech in Poland’s Reimbursement Landscape

Biotech medicines occupy a unique and strategically important position within Poland’s pharmaceutical reimbursement ecosystem. Although regulated under the same legal framework as traditional pharmaceuticals, biologic and advanced therapeutic products enter a far more complex and scrutinised pathway, shaped by higher uncertainty, higher costs, and greater system-wide economic impact.

1. Biotech’s Dominance in Drug Programmes (B-Programmes)

Most innovative biologics—especially oncology, immunology, and rare disease products—are not reimbursed through standard outpatient lists. Instead, they are funded via NFZ drug programmes (B-programmes), which impose:

Strict clinical entry criteria
Stepwise treatment algorithms
Hospital-based monitoring requirements
Mandatory real-world data reporting

These programmes act as a hybrid between reimbursement and controlled, protocol-driven access. As a result, biotech companies must design reimbursement dossiers that address not only HTA but also clinical pathway complexity.

2. Significantly Higher Evidence Requirements

AOTMiT applies deeper scrutiny to biotech submissions because biologics typically present:

Smaller or heterogeneous clinical trial populations
Surrogate endpoints rather than long-term outcomes
Limited post-market evidence at launch
Higher structural uncertainty in modelling

Manufacturers must provide robust sensitivity analyses, long-term extrapolations, and transparent uncertainty management, as weak modelling assumptions often lead to unfavourable HTA conclusions.

3. Biotech and ICER Pressure

Biologics often generate ICERs far above traditional willingness-to-pay levels.
To be recommended, companies must use:

Innovative managed entry agreements
Conditional pricing
Budget impact caps
Outcomes-based components (increasingly encouraged)

Because biologics disproportionately drive NFZ drug spending, budget impact is one of the dominant decision-making criteria.

4. EU HTA Regulation (2025): Biotech Will Be First to Feel the Impact

Under the new EU HTA Regulation, oncology biologics, ATMPs, and advanced therapies will be among the first technologies subject to joint clinical assessments (JCA) at the EU level.

For Poland, this means:

AOTMiT will no longer perform full clinical evidence reviews for these products
Clinical assessment will come from the EU
Poland will focus on economic modelling, cost-effectiveness, and budget impact
Submissions must be “JCA-ready” at launch

Biotech manufacturers must prepare European-standard clinical dossiers and align Polish submissions with EU HTA timelines.

5. Biosimilars and Market Competition

Poland is an aggressive adopter of biosimilars, which strongly influence pricing policy:

Mandatory price reductions after biosimilar entry
Rapid reshaping of reference pricing groups
Strong NFZ encouragement of biosimilar prescribing

This increases economic pressure on originator biologics and shapes negotiation strategies.

6. The Strategic Role of Digital Tools in Biotech

Digital health technologies can dramatically strengthen biotech submissions through:

Real-world evidence generation (treatment response, adherence, dosage patterns)
Outcome tracking for MEAs
Patient-reported outcomes (PROs) for QALY modelling
Digital biomarkers improving early detection of treatment effect
Companion digital monitoring for oncology and immunology pathways

Digitalisation does not have its own reimbursement pathway—but it enhances the value proposition for biologics in HTA.

Pharmaceutical reimbursement in Poland remains one of Europe’s most predictable and evidence-driven systems, and this is exactly what gives manufacturers an advantage—if they understand how the system thinks. AOTMiT’s discipline, NFZ’s cost constraints, and the Ministry’s pricing authority create a reimbursement environment where clarity, transparency and economic realism matter more than rhetoric.

Poland rewards companies that respect its logic: strong comparative evidence, defensible models, realistic budget forecasts, and early alignment with Polish clinical practice. It penalises overstatement, selective data use, and optimistic extrapolation.

As EU HTA rules reshape clinical assessment and Poland tightens its economic governance, the manufacturers who adapt early—scientifically, economically, and strategically—will navigate the system with confidence. In a European landscape where reimbursement pathways are increasingly fragmented, Poland’s structure is not a barrier but an asset: a coherent framework that consistently rewards high-quality evidence and credible value propositions.

Reference List Poland Pharmaceutical Reimbursement (2025)

1. Ministry of Health of Poland (Ministerstwo Zdrowia)

Website: https://www.gov.pl/web/zdrowie
Description:
The Ministry of Health is the central authority responsible for national pharmaceutical policy, drug reimbursement decisions, pricing approvals, and publication of reimbursement lists. It issues the quarterly “Obwieszenie” (Official Reimbursement Announcement).

2. AOTMiT — Agency for Health Technology Assessment and Tariffication

Website: https://www.aotm.gov.pl
Description:
Poland’s HTA agency performs all clinical and economic assessments for pharmaceuticals, medical technologies, and benefit baskets. AOTMiT recommendations form the evidentiary basis for national reimbursement decisions.

3. Polish National Health Fund (NFZ – Narodowy Fundusz Zdrowia)

Website: https://www.nfz.gov.pl
Description:
The NFZ finances publicly funded medicines and healthcare services. It manages co-payment rules, reference pricing clusters, drug funding limits, and outpatient reimbursement budgets.

4. Reimbursement Act (Ustawa Refundacyjna, 12 May 2011)

Text: https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20111220696
Description:
The cornerstone legislation governing reimbursement of medicines and medical devices in Poland. Defines HTA rules, pricing negotiations, managed entry agreements (MEAs), co-payment structures, and obligations of manufacturers.

5. Official Reimbursement List – Ministry of Health (Obwieszenie)

Archive: https://www.gov.pl/web/zdrowie/obwieszczenia-refundacyjne
Description:
Quarterly announcements listing all reimbursed drugs, reimbursement categories, levels of co-payment, and reference pricing groups. The primary operational tool for pharmacists, prescribers, and manufacturers.

6. European Network for Health Technology Assessment (EUnetHTA)

Website: https://www.eunethta.eu
Description:
Provides methodological frameworks adopted by AOTMiT for HTA evaluations. Poland aligns strongly with EUnetHTA and EU-wide HTA practices.

7. OECD Health Statistics – Poland Health System Indicators

Poland Profile: https://data.oecd.org/healthres/health-spending.htm
Description:
Compares Polish healthcare spending, pharmaceutical expenditure, and out-of-pocket costs with other OECD countries. Essential for benchmarking national affordability and budget impact.

8. WHO – Pharmaceutical Pricing and Reimbursement Policies in Europe

Report: https://www.euro.who.int/en/health-topics/Health-systems/medicines
Description:
WHO’s analysis of European pricing and reimbursement systems, including Poland’s use of reference pricing, co-payments, and HTA requirements.

9. European Commission – EU HTA Regulation (2025 Implementation)

Regulation Text: https://health.ec.europa.eu/health-technology-assessment-eu-level_en
Description:
The new EU HTA Regulation harmonises clinical assessments across Member States. Relevant for Poland as it will influence AOTMiT’s processes and dossier requirements from 2025 onward.

10. CADTH Glossary of HTA and Economic Evaluation Terms

Glossary: https://www.cadth.ca/glossary
Description:
Authoritative resource for definitions used in HTA, cost-effectiveness modelling, ICERs, QALYs, and budget impact analysis. Useful for interpreting AOTMiT methods.

11. Frontiers in Pharmacology – Comparative Study on Polish Reimbursement System

Paper:
https://www.frontiersin.org/articles/10.3389/fphar.2023.1153680/full
Description:
Peer-reviewed 2023 systematic review comparing Poland’s reimbursement systems with other European and international models. Strong academic evidence on structural features and HTA rigor.

12. Pharmaceutics Journal – Real-World Data on Generic Substitution in Poland

Paper:
https://www.mdpi.com/1999-4923/13/8/1165
Description:
Large-scale analysis of Poland’s real-world prescription and substitution data. Demonstrates the economic impact of generic substitution on NFZ expenditures and patient co-payments.

13. Polish Drug Registration Authority (URPL – Office for Registration of Medicinal Products)

Website: https://www.urpl.gov.pl
Description:
Handles marketing authorisation in Poland for pharmaceuticals and medical devices. Regulatory entry step before reimbursement.

14. Government Centre for Legislation – Polish Law Database (ISAP)

Website: https://isap.sejm.gov.pl
Description:
Official government repository of Polish laws and regulations, including updates to pharmaceutical, reimbursement, and health policy legislation.

15. Statista – Pharmaceutical Market in Poland (Market Data)

Poland Pharma Overview: https://www.statista.com/topics/3870/pharmaceutical-market-in-poland/
Description:
Provides market size, spending trends, prescription volumes, and industry analytics. Useful supporting data for blogs or reports.

AQs: Pharmaceutical Reimbursement in Poland

1. How does pharmaceutical reimbursement in Poland work?

Poland uses a highly structured, centralised pathway based on three pillars:
AOTMiT’s HTA assessment, NFZ’s financial sustainability analysis, and Ministry of Health pricing decisions.
Every reimbursed medicine must undergo:

a full clinical effectiveness review
comparative analysis against the Polish standard of care
cost-effectiveness modelling (ICER/QALY)
Polish-specific EQ-5D utility weighting
multiyear budget impact forecasting

Only after HTA, negotiation, and reference pricing assignment can a product be placed on the official reimbursement list (Obwieszczenie Refundacyjne).

2. What evidence does AOTMiT require for reimbursement?

AOTMiT expects a complete HTA dossier aligned with EUnetHTA and NICE methodology. This typically includes:

systematic literature reviews
robust comparator justification
survival modelling (partitioned survival or Markov)
deterministic and probabilistic sensitivity analyses
calibration of long-term extrapolations to Polish epidemiology
scenario analyses for treatment switching and attrition
transparent handling of structural uncertainty

AOTMiT places particular emphasis on model validity, uncertainty reduction, and realistic assumptions around long-term outcomes, especially in oncology.

3. How important is budget impact in Poland’s reimbursement decisions?

Budget impact is often the decisive factor in pharmaceutical reimbursement in Poland. NFZ evaluates:

expected treatment uptake
eligible population size (often recalibrated by NFZ)
displacement of current therapies
downstream hospitalisation costs
long-term pressure on outpatient budgets

A high ICER can be tolerated for small populations, but large-population therapies face stricter affordability thresholds.
NFZ frequently requires:

price-volume agreements
mandatory refunds when caps are exceeded
risk-sharing arrangements

This is why budget impact analysis (BIA) must be accurate, conservative, and evidence-based for Polish decision-makers.

4. What role do Drug Programmes (B-Programmes) play?

B-Programmes are central to the reimbursement of biologics and high-cost advanced therapies in Poland. These programmes function as clinical governance frameworks and include:

defined eligibility criteria
stopping rules
mandated biomarker testing (CDx)
structured monitoring intervals
compulsory real-world evidence (RWE) reporting to NFZ
centralised national funding

They allow early access while ensuring rational use and cost control.
For pharmaceutical manufacturers, B-Programmes are often the primary gateway to the Polish oncology, immunology, and rare disease markets.

5. How will EU HTA rules affect reimbursement in Poland in 2026?

Beginning in 2025, joint clinical assessments (JCAs) under the EU HTA Regulation will determine the comparative clinical evidence for high-impact technologies, particularly oncology and ATMPs.
Poland will continue to conduct:

national economic evaluations (ICER/QALY)
Polish-specific budget impact analyses
organisational impact assessments

However, manufacturers must now produce evidence packages that satisfy both:
EU-level clinical harmonisation and Polish national economic requirements.

This reshapes strategy: companies must align Polish submissions with EU timelines while ensuring their models fit NFZ affordability constraints.

6. Is Poland an attractive market for innovative medicines?

Yes—particularly for companies with strong evidence and realistic economic positioning.
Poland’s system is demanding but predictable, and offers:

clear HTA methodology
stable legal framework
structured pathways for biologics (B-Programmes)
increasing acceptance of digital RWE
national, not regional, decision-making

The country is highly cost-sensitive, but manufacturers who provide high-quality modelling, credible pricing, and well-defined target populations often achieve successful reimbursement.

7. What cost-effectiveness thresholds are used in Poland?

Poland no longer publishes an official threshold, but AOTMiT still references the historical benchmark of ~3×GDP per capita per QALY as an implicit guide for judging ICER acceptability.
In oncology and other high-budget categories, practical thresholds often fall to 1–2×GDP per QALY, driven by NFZ affordability constraints.
For SEO: this reinforces “cost-effectiveness”, “ICER”, “QALY”, “pharmaceutical reimbursement in Poland”.

8. How are companion diagnostics (CDx) reimbursed in Poland?

Poland does not operate an independent reimbursement pathway for CDx.
Instead, CDx is funded within drug programmes, meaning:

test costs are bundled into the therapy’s total funding
diagnostic performance influences the HTA outcome
CDx must be justified in the economic model as part of the value pathway

This integrated approach ensures equitable access but demands that manufacturers model the diagnostic–treatment pathway holistically.

9. How important is real-world evidence (RWE) in Polish HTA?

RWE is increasingly important, especially for biologics and therapies launched with immature survival data.
RWE helps reduce:

long-term survival uncertainty
utility estimation uncertainty
treatment duration assumptions
discontinuation rates
crossover effects

AOTMiT values Polish or Central European RWE highly, as it improves the credibility of cost-effectiveness models and budget impact forecasts.

10. What pricing mechanisms does Poland use to control pharmaceutical spending?

Poland uses a combination of:

reference pricing (ATC-based)
mandatory post-exclusivity price cuts
managed entry agreements
budget caps and refunds
strict co-pay structures
quarterly reimbursement list updates

These collectively create a high-cost-pressure environment, but one that is predictable and rules-based.

How Poland’s Pharmaceutical Reimbursement System Really Works in 2026: How to use it.